BC3 Technologies receives patent for SEAL Hemostatic Wound Spray

BC3 Technologies, a Baltimore-based, minority-owned company addressing emergency medical response and trauma care, has received a U.S. patent that protects its proprietary material, chemistry, technology, and method of its product SEAL Hemostatic Wound Spray for rapid and efficient management of severe bleeding.
The U.S. Patent and Trademark Office issued BC3 Technologies, Inc. patent US12,263,185 for its hemostatic material and spray method of treating a bleeding wound of a human or an animal.
“With this patent, we are pleased to have the formal protection of our material and method for our product SEAL as we enhance trauma care and emergency medical response,” shared Wayne Grube, CEO and Co-Founder, BC3 Technologies. “When realising there was a void in the market for managing and controlling those challenging life-threatening wounds quicker than with the traditional pressure and gauze solution or powder chitosan, we began our development of our innovative chitosan base and salt mixture to be dispersed in a liquefied gas for release from a cannister onto the wound. When seconds matter most, we now have a product to help save lives.”
SEAL Hemostatic Would Spray is the first and only FDA-cleared aerosolised chitosan for rapid management of serious arterial bleeding.
Marking a significant advancement in emergency medical response and trauma care, SEAL is an innovative patented product that acts as a strong physical barrier, effectively and quickly sealing wounds to stop blood flow within seconds.
Unlike bandage or granule-based chitosan products, SEAL can be applied under windy and wet conditions and in low-light.
The product is compact, easy to carry, and can be administered by first responders, professional medical staff, military, patients, or caregivers.
SEAL Pro is available as a 2.5 oz single use spray and SEAL OTC a 1.5 oz single use spray.
BC3 Technologies has developed several supporting accessories, including first aid kits and SEAL holders, that allow for quick deployment of the lifesaving product for first responders and the public.
SEAL was invented by Dr. Thomas Freier, Head of R&D; Dr. Rivelino Montenegro, Head of Regulatory Affairs; and Wayne Grube, Jr., CEO and Co-Founder for BC3 Technologies.
The clinical results so far have been highly promising in rapidly stopping blood loss and significantly enhancing survival rates, especially in situations where immediate medical response is delayed. SEAL is currently being used by first responders, in surgical environments, and in battlefield combat globally to bridge the gap in emergency medical care.
Partnerships with esteemed local and national organisations such as University of Maryland Shock Trauma and MIEMSS, as well as Fire and Police departments, EMS systems, and school systems have allowed BC3 Technologies to refine their product and design supporting tools for quicker deployments and increased likelihood of survival for those affected during traumatic events.